Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China

Overview of attention for article published in Frontiers in Pharmacology, September 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 14 Mendeley

So far, Altmetric has seen 1 X post from an account with 5,881 followers.

New Research: Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China https://t.co/c0GE7OF8f0 #pharmacology

01 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.